Afinitor

Pharma

Merck's Welireg again comes up short in OS but excels in PFS

Merck’s Welireg continues to show benefits in PFS but no significant improvement in overall survival when compared to Novartis’ chemotherapy Afinitor.

Kevin Dunleavy Sep 13, 2024 8:00am

At ESMO, Merck touts Welireg's potential in kidney cancer

Oct 21, 2023 9:00am

Merck looks to broaden Welireg's reach in kidney cancer

Aug 18, 2023 11:12am

Novartis social media campaign on breast cancer health inequities

Novartis' campaign tackles inequities in breast cancer health

Jun 14, 2021 8:00am

Person speaking onstage at ESMO 2019 in Barcelona

Chasing Novartis, Chi-Med posts neuroendocrine cancer win

Sep 30, 2019 9:55am

Novartis wins FDA nod for newly acquired cancer drug Lutathera

Jan 26, 2018 3:10pm